Cargando…
Conservative Iron Chelation for Neuroferritinopathy
BACKGROUND: Neuroferritinopathy is a rare inherited neurodegenerative disease with brain iron accumulation characterized by brain iron overload resulting in progressive movement disorders. No treatment is currently available. OBJECTIVE: We assessed conservative iron chelation with deferiprone at 30 ...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360136/ https://www.ncbi.nlm.nih.gov/pubmed/35996824 http://dx.doi.org/10.1002/mds.29145 |
_version_ | 1785076036234379264 |
---|---|
author | Marchand, Felix Moreau, Caroline Kuchcinski, Gregory Huin, Vincent Defebvre, Luc Devos, David |
author_facet | Marchand, Felix Moreau, Caroline Kuchcinski, Gregory Huin, Vincent Defebvre, Luc Devos, David |
author_sort | Marchand, Felix |
collection | PubMed |
description | BACKGROUND: Neuroferritinopathy is a rare inherited neurodegenerative disease with brain iron accumulation characterized by brain iron overload resulting in progressive movement disorders. No treatment is currently available. OBJECTIVE: We assessed conservative iron chelation with deferiprone at 30 mg/kg/day on the disease progression with controlled periods of discontinuation. METHODS: Four patients with confirmed molecular diagnosis of neuroferritinopathy were given deferiprone at different stages of disease progression and with clinical and biological monitoring to control benefit and risk. RESULTS: The four patients showed slight to high improvement. In one case, we managed to stabilize disease progression for more than 11 years. In another case, we were able to reverse symptoms after a few months of treatment. The earliest the treatment was started, the most efficient it was on disease progression. CONCLUSIONS: Conservative iron chelation should be further assessed in neuroferritinopathy. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
format | Online Article Text |
id | pubmed-10360136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103601362023-07-22 Conservative Iron Chelation for Neuroferritinopathy Marchand, Felix Moreau, Caroline Kuchcinski, Gregory Huin, Vincent Defebvre, Luc Devos, David Mov Disord Regular Issue Articles BACKGROUND: Neuroferritinopathy is a rare inherited neurodegenerative disease with brain iron accumulation characterized by brain iron overload resulting in progressive movement disorders. No treatment is currently available. OBJECTIVE: We assessed conservative iron chelation with deferiprone at 30 mg/kg/day on the disease progression with controlled periods of discontinuation. METHODS: Four patients with confirmed molecular diagnosis of neuroferritinopathy were given deferiprone at different stages of disease progression and with clinical and biological monitoring to control benefit and risk. RESULTS: The four patients showed slight to high improvement. In one case, we managed to stabilize disease progression for more than 11 years. In another case, we were able to reverse symptoms after a few months of treatment. The earliest the treatment was started, the most efficient it was on disease progression. CONCLUSIONS: Conservative iron chelation should be further assessed in neuroferritinopathy. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. John Wiley & Sons, Inc. 2022-08-22 2022-09 /pmc/articles/PMC10360136/ /pubmed/35996824 http://dx.doi.org/10.1002/mds.29145 Text en © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Regular Issue Articles Marchand, Felix Moreau, Caroline Kuchcinski, Gregory Huin, Vincent Defebvre, Luc Devos, David Conservative Iron Chelation for Neuroferritinopathy |
title | Conservative Iron Chelation for Neuroferritinopathy |
title_full | Conservative Iron Chelation for Neuroferritinopathy |
title_fullStr | Conservative Iron Chelation for Neuroferritinopathy |
title_full_unstemmed | Conservative Iron Chelation for Neuroferritinopathy |
title_short | Conservative Iron Chelation for Neuroferritinopathy |
title_sort | conservative iron chelation for neuroferritinopathy |
topic | Regular Issue Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360136/ https://www.ncbi.nlm.nih.gov/pubmed/35996824 http://dx.doi.org/10.1002/mds.29145 |
work_keys_str_mv | AT marchandfelix conservativeironchelationforneuroferritinopathy AT moreaucaroline conservativeironchelationforneuroferritinopathy AT kuchcinskigregory conservativeironchelationforneuroferritinopathy AT huinvincent conservativeironchelationforneuroferritinopathy AT defebvreluc conservativeironchelationforneuroferritinopathy AT devosdavid conservativeironchelationforneuroferritinopathy |